concept

DISEASE PROGRESSION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DISEASE PROGRESSION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

50Connections

0Hypotheses

17Analyses

2Outgoing

48Incoming

0Experiments

10Debates

No summary available yet. View on Wiki →

No AI portrait yet

💡 Concept Info

Name	DISEASE PROGRESSION

Wiki Pages (20)

Knowledge base pages for this entity

cbs-psp-daily-action-plan

therapeutic · 30834 words

→

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

→

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

→

Clinical Management Guide for CBS/PSP

therapeutic · 15224 words

→

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

→

Pathway Diagram

graph TD
    DISEASE_PROGRESSION["DISEASE PROGRESSION"]
    DISEASE_PROGRESSION -->|"involved_in"| Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
    Neuroinflammation["Neuroinflammation"] -->|"regulates"| DISEASE_PROGRESSION
    Extracellular_Matrix["Extracellular Matrix"] -->|"contributes to"| DISEASE_PROGRESSION
    Neuronal_Damage["Neuronal Damage"] -->|"contributes to"| DISEASE_PROGRESSION
    Neurodegeneration_Markers["Neurodegeneration Markers"] -->|"correlates_with"| DISEASE_PROGRESSION
    Poor_Cognitive_Function["Poor Cognitive Function"] -->|"correlates_with"| DISEASE_PROGRESSION
    Oligodendrocytes["Oligodendrocytes"] -->|"contributes to"| DISEASE_PROGRESSION
    Astrocytes["Astrocytes"] -->|"contributes to"| DISEASE_PROGRESSION
    NDNF_Overexpression["NDNF Overexpression"] -->|"inhibits"| DISEASE_PROGRESSION

Outgoing (2)

Target	Relation	Type	Str
Neuroinflammation	associated_with	process	0.85
Amyotrophic Lateral Sclerosis	involved_in	disease	0.85

Incoming (48)

Source	Relation	Type	Str
Donanemab	inhibits	drug	0.95
PI3K/Akt/mTOR	involved_in	pathway	0.90
Abnormal Stress Granule Accumulation	contributes_to	phenotype	0.90
Somatic Mutations In Hematopoietic Stem Cells	contributes_to	process	0.90
Neuroinflammation	regulates	process	0.90
PIKFYVE	inhibits	protein	0.90
Extracellular Matrix	contributes_to	process	0.88
PIKFYVE inhibition	associated_with	process	0.88
Neuronal Damage	contributes_to	phenotype	0.87
Neurodegeneration Markers	correlates_with	biomarker	0.87
Poor Cognitive Function	correlates_with	phenotype	0.85
Oligodendrocytes	contributes_to	cell_type	0.85
NDNF Overexpression	inhibits	process	0.85
Extracellular Matrix	modulates	process	0.85
Cerebrospinal Fluid	associated_with	biomarker	0.85
Cerebral Perfusion	correlates_with	biomarker	0.85
SNCA	contributes_to	protein	0.85
Mitochondria	involved_in	cell_type	0.85
pS65-Ubiquitin	correlates_with	biomarker	0.85
Neuromodulation	modulates	process	0.85
Gray Matter Perfusion	correlates_with	biomarker	0.85
Tofersen	suppresses	drug	0.85
SNCA fibril polymorphs	contributes_to	protein	0.85
Amyloid Clearance	modulates	process	0.85
Early Treatment Initiation	suppresses	mechanism	0.85
NPY	biomarker_for	protein	0.85
Astrocytes	contributes_to	cell_type	0.85
Amyotrophic Lateral Sclerosis	causes	disease	0.85
Gene Therapy	modulates	drug	0.85
Metabolomic Profiles	biomarker_for	biomarker	0.82
MTOR	associated_with	pathway	0.82
Protective Genetic Variants	modulates	biomarker	0.82
Tumor Diversity	associated_with	phenotype	0.80
M1 Microgliosis	contributes_to	cell_type	0.80
Cell-To-Cell Transmission	contributes_to	process	0.80
RELN	modulates	gene	0.80
Differentially Expressed Genes	biomarker_for	biomarker	0.75
Neuromodulation	inhibits	process	0.75
Astrogliosis	contributes_to	process	0.75
ncRNA-based therapies	suppresses	drug	0.75
Ncrna-Based Therapies	suppresses	drug	0.75
SARM1	involved_in	gene	0.75
C1Q	regulates	protein	0.70
huntingtin knockdown	protects_against	process	0.70
Individualized Treatment	modulates	process	0.70
intercellular propagation	promotes	process	0.70
TMEM106B genetic variation	regulates	gene	0.70
EARLY COMPLEMENT GENES	drives	gene	0.70

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (17)

Scientific analyses that reference this entity

Cell-Cell Communication Analysis in AD Brain Microenvironment

neurodegeneration | 2026-04-16 | 0 hypotheses

Spatial Transcriptomics Analysis of Alzheimer's Disease Brain Regions

neurodegeneration | 2026-04-16 | 0 hypotheses

Systemic immune profiling in neurodegeneration: peripheral inflammation as drive

immunomics | 2026-04-16 | 0 hypotheses

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging br

metabolomics | 2026-04-16 | 0 hypotheses

What are the specific molecular determinants that govern tau strain selection du

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.636

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (10)

Multi-agent debates referencing this entity

Is the APOE-TREM2 communication axis a therapeutic target, or is disrupting it r

closed · Rounds: 4 · Score: 0.48 · 2026-04-16

Do spatial transcriptomic neighborhoods provide sufficient discriminative power

closed · Rounds: 4 · Score: 0.40 · 2026-04-16

Both compounds similarly reduced aging hallmarks (AMPK, Nrf2, COX IV1) and infla

closed · Rounds: 4 · Score: 0.68 · 2026-04-16

The debate highlighted tau prion-like transmission but did not resolve how diffe

closed · Rounds: 4 · Score: 0.57 · 2026-04-15

Which metabolic biomarkers can distinguish therapeutic response from disease pro

closed · Rounds: 4 · Score: 0.77 · 2026-04-12

How do astrocyte-neuron metabolic interactions change during disease progression

closed · Rounds: 4 · Score: 0.86 · 2026-04-12

How do host cell factors influence the conformation and propagation properties o

closed · Rounds: 4 · Score: 0.95 · 2026-04-10

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

closed · Rounds: 4 · Score: 0.94 · 2026-04-10

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

closed · Rounds: 4 · Score: 0.59 · 2026-04-02

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

closed · Rounds: 4 · Score: 0.46 · 2026-04-02

DISEASE PROGRESSION

Understanding Entity Pages

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Parkinson's Disease

Sleep and Circadian Dysfunction in Alzheimer's Disease

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

primary-progressive-aphasia

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

Parthanatos in Neurodegeneration

CBS/PSP Rehabilitation Master Guide

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

PD Combination Therapy Matrix

Corticobasal Degeneration (CBD)

Pathway Diagram

Outgoing (2)

Incoming (48)

Targeting Hypotheses (0)

Mentioning Analyses (17)

Cell-Cell Communication Analysis in AD Brain Microenvironment

Spatial Transcriptomics Analysis of Alzheimer's Disease Brain Regions

Systemic immune profiling in neurodegeneration: peripheral inflammation as drive

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging br

What are the specific molecular determinants that govern tau strain selection du

Why does Metformin fail to delay CJD progression despite improving anti-aging ha

What is the temporal sequence of sleep disruption versus amyloid-beta accumulati

Are autophagy-lysosome defects primary drivers or downstream consequences in spo

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

How do host cell factors influence the conformation and propagation properties o

What determines organelle-specific autophagy selectivity in neurodegenerative di

What determines P2RY12 receptor expression/activity specifically in VSMCs during

Which metabolic biomarkers can distinguish therapeutic response from disease pro

How do astrocyte-neuron metabolic interactions change during disease progression

Metabolomic signatures of neurodegeneration and energy metabolism dysfunction

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

Experiments (0)

Related Papers (0)

Debates (10)

Is the APOE-TREM2 communication axis a therapeutic target, or is disrupting it r

Do spatial transcriptomic neighborhoods provide sufficient discriminative power

Both compounds similarly reduced aging hallmarks (AMPK, Nrf2, COX IV1) and infla

The debate highlighted tau prion-like transmission but did not resolve how diffe

Which metabolic biomarkers can distinguish therapeutic response from disease pro

How do astrocyte-neuron metabolic interactions change during disease progression

How do host cell factors influence the conformation and propagation properties o

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi

Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi